Aug 05, 2021
Surrozen to Present at Canaccord Genuity’s 41st Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., August 5, 2021 – Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Craig Parker, chief executive officer, will provide a company overview and a business update at Canaccord
Jul 09, 2021
Surrozen Presents New Data Demonstrating Superior Activity of SZN-1326 in Preclinical Inflammatory Bowel Disease Models at 16th Congress of the European Crohn’s and Colitis Organisation (ECCO)
—  Company to advance SZN-1326 toward first-in-human clinical studies in 2022  — SOUTH SAN FRANCISCO, Calif., July 9, 2021 – Surrozen Inc., a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, announced today that new data from its inflammatory
Displaying 1 - 10 of 13